AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06312228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helfer Skin Tap
Description: Slow tapping was performed with rhythmic tapping movements on the left deltoid muscle where the vaccine will be administered to the children. When the needle was to be inserted into the deltoid muscle, the tapping was slightly increased and the needle entry was made with the same movement. After the vaccine injection was given, the needle was rapidly withdrawn from the muscle by increasing the tapping movements while the needle was withdrawn.
Study NCT06312228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: The ice pack previously removed from the deep freezer was kept at room temperature for 10 minutes and the hole in the ice pack wing was placed on the hook behind the Buzzy®. The Buzzy® was placed on the left arm deltoid muscle and activated and kept for 30 seconds. After 30 seconds, Buzzy® was pulled up 1 centimetre (cm) and the MMR vaccine injection was administered to the area corresponding to the left deltoid muscle. After the vaccine injection, Buzzy® was pulled to the injection site and kept for another 30 seconds.
Study NCT04939610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAP-2286
Description: 68Ga-FAP-2286 IV administered as imaging agent for PET scan.
Study NCT04939610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-FAP-2286
Description: Phase 1:~Patients with positive uptake of 68Ga-FAP- 2286 will receive a fixed dose of 177Lu-FAP-2286 IV administered every 6 weeks for a maximum of 6 doses. Doses range between 3.7 and 9.25 GBq (100-250 mCi).~Phase 2:~Monotherapy: Patients with positive uptake of 68Ga FAP 2286 will receive a fixed dose of 177Lu FAP 2286 IV administered at the RP2D determined in Phase 1 dose escalation in every 4 weeks.~Combination therapy: Patients with positive uptake of 68Ga FAP 2286 will receive 177Lu-FAP-2286 based on dose escalation (starting with dose level 1) followed by dose expansion at selected dose.
Study NCT05294978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography (OCT)
Description: Data of macular optical coherence tomography (OCT)
Study NCT04892823 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample
Study NCT04892823 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT04892823 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT05611151 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computer Aided Detection (CADe)
Description: Computer-aided detection (CADe) devices are used in conjunction with colonoscopy to aid in the detection of lesions in the gastrointestinal tract.
Study NCT05611151 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computer Aided Detection (CADe)
Description: Computer-aided detection (CADe) devices are used in conjunction with colonoscopy to aid in the detection of lesions in the gastrointestinal tract.
Study NCT04945746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation
Description: AF ablation using the Volta Medical VX1 CE marked software and a new criteria to establish a priority of the dispersed zones according to the stability of the core algorithm's response (thanks to the new software module under study named stability).
Study NCT06399900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Far red light therapy
Description: All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
Study NCT06399900 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham light therapy
Description: All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
Study NCT06399900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based walking exercise
Description: This study involves a 16 week intervention where participants will walk at home for exercise with guidance from a study coach. Participants will have 4 in-person visits in the first four weeks and then have weekly phone calls in the last 12 weeks of the intervention with their coach.
Study NCT06399900 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Home-based walking exercise
Description: This study involves a 16 week intervention where participants will walk at home for exercise with guidance from a study coach. Participants will have 4 in-person visits in the first four weeks and then have weekly phone calls in the last 12 weeks of the intervention with their coach.
Study NCT05206708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized psychotherapy
Description: Strategy including personalized psychotherapy
Study NCT05206708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Strategy based standard intregrative psychodynamic therapy
Study NCT05665738 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose Rate Monotherapy
Description: High dose rate brachytherapy delivered in 13.5 Gy x 2 fractions over a single implant procedure 3 hours apart
Study NCT06234228 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Bluetooth Haptic Device (BHD)
Description: The BHD will deliver constant low-frequency vibration (CF).
Study NCT06234228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BHD synced with mobile game
Description: The BHD delivers a constant low-frequency vibration as well as tactile feedback from the game (GF).
Study NCT04880980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Pill
Description: Double than usual dose of oral terbinafine pills will be used for treatment purpose in one group.
Study NCT04880980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole capsule
Description: Double than usual dose of oral itraconazole capsules will be used for treatment purpose in second group.
Study NCT06016803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cicatryl (RL3010A - DP0378)
Description: Tested product is applied twice a day. The maximum duration of application is 7 days.
Study NCT05288153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will be instructed to take one tablet(500mg) of metformin after breakfast every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
Study NCT05288153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folate
Description: Subjects will be instructed to take one tablet(5mg) of folate three times every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
Study NCT06337084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNPR-101-DFO*-89Zr
Description: Participants will receive one dose of MNPR-101-DFO\*-89Zr infused intravenously on Day 1 for PET scans
Study NCT06337084 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Diagnostic Imaging
Description: PET/CT imaging will occur post-infusion at 2 h (Day 1), once on Days 3-5, and once on Days 7-10 for tumor lesion observation.
Study NCT06479642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve pulse radiofrequency ablation 3
Description: Ultrasound-guided genicular nerve radiofrequency therapy targets only the traditional 3 genicular nerves
Study NCT06479642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve pulse radiofrequency ablation 4
Description: Ultrasound-guided genicular nerve radiofrequency therapy targets only the traditional 3 genicular nerves and the intermedius genicular nerve in addition to the traditional genicular nerves.
Study NCT05572255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: 200 mg Cenobamate Tablet
Study NCT05488678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: single oral dose
Study NCT05488678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Description: single oral dose
Study NCT06210646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citicoline 2000
Description: The citicoline arm consists of 400 patients who received 2000 mg citicoline once daily for 12 months, and an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
Study NCT06210646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citocoline 1000
Description: The placebo arm consists of 400 patients who received a citicoline 1000 mg once daily for 12 months, an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
Study NCT05217615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ezParent
Description: The ezParent Program is a 6-module web-based adaptation of the group-based Chicago Parent Program (CPP). ezParent uses multiple strategies to promote skill development in parents. Each module includes (a) video narrator descriptions of parenting strategies, (b) video vignettes of parents and children as examples of how parenting strategies work, (c) questions following each vignette for parents to reflect upon, (d) interactive activities for parents to complete, (e) knowledge questions to assess parent understanding of the strategies, and (f) practice assignments. To tailor to the former VPT population, developmental tips are included. Parents are instructed to complete the 6 modules over 10-weeks, approximately 1 module every 1.5 weeks. At the end of each module, parents receive a practice assignment linked to the module content. To encourage and support program completion, parents receive automated text messages and badges.
Study NCT05217615 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching calls
Description: The purpose of the brief (\~15 min) telephone coaching calls is to provide parents with clarification of program content, encouragement and reinforcement of program completion, and support tailoring of intervention content (ezParent or Active Control)for their child. Coaching calls are guided by a semi-structured script aimed at supporting parent learning and motivation. Calls will be scheduled every week for 10 weeks. Each call will include an opportunity for parents to identify and discuss:(a) questions regarding the materials and content received in their respective groups,(b) identification of potential barriers and strategies to overcome barriers for completion of intervention (ezParent or control) content in their respective group, and (c)follow up on discussion points from previous calls. In both conditions, coaches will have access to a web-based usage portal to guide the discussion.
Study NCT05217615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching calls
Description: The purpose of the brief (\~15 min) telephone coaching calls is to provide parents with clarification of program content, encouragement and reinforcement of program completion, and support tailoring of intervention content (ezParent or Active Control)for their child. Coaching calls are guided by a semi-structured script aimed at supporting parent learning and motivation. Calls will be scheduled every week for 10 weeks. Each call will include an opportunity for parents to identify and discuss:(a) questions regarding the materials and content received in their respective groups,(b) identification of potential barriers and strategies to overcome barriers for completion of intervention (ezParent or control) content in their respective group, and (c)follow up on discussion points from previous calls. In both conditions, coaches will have access to a web-based usage portal to guide the discussion.
Study NCT05217615 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Active Control
Description: The active control is an adaptation of a web-based application developed in our previous study (R01-HS024273). The program will include general information typically provided during well-child or NICU follow up visits. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks, approximately 1 topic every 1.5 weeks
Study NCT04960189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture will be performed bilateral on fibular aspect of the leg, in the depression anterior and distal to the head of the fibula by using 0,25x50mm needles.
Study NCT05973695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clamshell exercise
Description: For clamshell exercises, Lie on your side with your knees slightly bent and with one leg on top of the other. Keep your feet together and lift your top knee until its parallel with your hip. Lower your knee back to the initial position, repeat, and then switch sides. In 1st week 1 sets 10 repetitions. In 2nd week 2 sets of 10 repetitions. In 3rd and 4th week and onwards 3 sets of 10 repetitions
Study NCT05973695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluteal Bridge exercises
Description: Start flat on your back with your legs bent at a 90-degree angle and feet placed flat on the ground. Make sure your toes are turned outward at 45-degree angles and your knees are facing in the same direction as your toes. Drive d
Study NCT05778669 — intervention group
Intervention type: OTHER
Intervention: Monitoring of medical, health and psychosocial conditions
Description: Questionnaires will be used to collect information including children's health and psychosocial conditions, academic performance, and family demographics.~On-site assessments including general health and learning assessments.~Tracking of medical and health-related events of participants will be performed through the existing health care system.
Study NCT06417567 — intervention group
Intervention type: DRUG
Intervention: NEPA
Description: NEPA in Preventing Postoperative Nausea and Vomiting after General Anesthesia Gastrointestinal Cancer Surgery
Study NCT04584775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment modalities of Traditional Chinese Medicine (Acupuncture, Chinese herbal medicine, Tunia, Chinese dietetics)
Description: Acupuncture is a physical treatment modality that uses thin needles to stimulate specific points on the body in order to manipulate neurologic mechanisms to control specific symptoms and/or physiologic processes.~Chinese herbal medicine is a phytotherapeutic treatment modality that uses herbs, minerals and rarely animal products which are orally administered.~Tuina is a form of massage and physical therapy. Chinese dietetics is a nutritional therapy according to the theoretical principle of traditional Chinese medicine.
Study NCT04584775 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care includes any medical intervention in palliative care that aims to promote and/or sustain the quality of life of patients suffering from advanced disease (in this case cancer). These may be of pharmaceutical, surgical, psychological and/or spiritual nature.
Study NCT04584775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care includes any medical intervention in palliative care that aims to promote and/or sustain the quality of life of patients suffering from advanced disease (in this case cancer). These may be of pharmaceutical, surgical, psychological and/or spiritual nature.
Study NCT05970679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Atorvastatin 10/5 mg
Description: DW1125
Study NCT05970679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 5mg
Description: DW1125A
Study NCT05970679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe 10mg
Description: DW1125E
Study NCT05970679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 10mg
Description: DW1125A-1
Study NCT05970679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1125 placebo
Description: Ezetimibe/Atorvastatin 10/5 mg placebo
Study NCT05970679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DW1125 placebo
Description: Ezetimibe/Atorvastatin 10/5 mg placebo
Study NCT05970679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1125A placebo
Description: Atorvastatin 5mg placebo
Study NCT05217615 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The active control is an adaptation of a web-based application developed in our previous study (R01-HS024273). The program will include general information typically provided during well-child or NICU follow up visits. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks, approximately 1 topic every 1.5 weeks
Study NCT05656534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). Suvorexant (SUV) will be placed in opaque capsules with dextrose filler. After the pre-treatment visits participants will take one pill of SUV at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete an EMG. Laboratory assessments will occur during peak concentration, 2 hours post-ingestion. At the end of the visit, participants will be given a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side effects and potential drug-drug interactions. At the end of the 28 days, participants will complete post-treatment lab visits.
Study NCT05656534 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). The placebo pill will be identical in appearance to suvorexant but will contain only dextrose. Following the pre-treatment visits, participants will take one pill at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete the EMG paradigm. At the end of the visit participants will be provided a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side. At the end of the 28 days, participants will complete post-treatment lab visits.
Study NCT06117306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4 Methylenedioxymethamphetamine
Description: 1 MDMA session
Study NCT06117306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: 12 90-minute PE sessions; initial two sessions both occurring during the first treatment visit, third and fourth sessions occurring during the MDMA session, and the remaining sessions occurring daily or every other day
Study NCT05157386 — intervention group
Intervention type: OTHER
Intervention: Braining
Description: Core components of Braining: Personnel-led training sessions, motivating contact with psychiatric staff, measurement and evaluation before and after the training period; usually 12 weeks. PE is added on to treatment as usual (TAU). The training sessions are moderate to intense aerobic group training, 30-45 minutes. Each training session is preceded by a short (5-10 minutes) individual meeting with staff including assessment of daily form, motivational work, and the opportunity to ask questions. The target frequency for participation is preferably at least three training sessions/week during a 12 week period. The training period for each patient begins with an informative and motivating group or individual lecture or and an individual introductory meeting with staff including psychiatric and somatic examination, self-assessment scales for symptoms and quality of life, and blood samples. The training period ends with a meeting with staff with follow-up on the parameters.
Study NCT04921436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac surgery
Description: prophylactic use of antibiotic-inhibitors